Octylgermane on gold: synthesis, oxidation, and pattern formation

Chemisorbed monolayers of octylgermane (C8H17GeH3) on gold have been formed by vapor deposition in ultrahigh vacuum. The monolayer has been characterized by X-ray photoelectron and reflection absorption infrared spectroscopies (XPS and RAIRS) and scanning tunneling microscopy (STM). XPS data indicate the monolayer can be oxidized by exposure to ozone. STM images exhibit a complex pattern which can be modeled as strain-mediated spinodal decomposition.     

Regiospecific photoisomerization of fluorinated (E,E)-1,4-diphenyl-1,3-butadienes

Photoisomerization of five fluorinated E,E-1-(R-phenyl)-4-phenyl-1,3-butadienes in solution (R = 1: p-monofluoro, 2: m,m′-difluoro, 3: m,m′,p-trifluoro, 4: o,o′,m,m′-tetrafluoro, 5: o,o′,m,m′,p-pentafluoro) was investigated via direct irradiation. Our results indicated that cis-trans photoisomerization of the fluorinated 1,4-diphenyl-1,3-butadienes in the excited singlet state took place exclusively at the CC bonds closer to the fluorine substituents.     

PHOTOPEROXIDATION OF LENS LIPIDS: PREVENTION BY VITAMIN E

Abstract— Light of visible frequency was observed to initiate peroxidative degradation of lipids of rat lenses when the latter were maintained in organ culture. The extent of degradation was monitored by measurement of malanaldehyde. This photodegradative process, which we believe is triggered by light catalyzed generation of superoxide and its subsequent transformation to other potent oxidants. was observed to be thwarted substantially if the medium of organ culture was fortified with 10⁻³ and 10⁷ M vitamin E (α-tochopherol). These studies suggest that vitamin E may be metabolically beneficial by protecting light exposed tissues, such as those in the eye against photoperoxidativc damage concomitant to light-catalyzed generation of oxygen-free radicals. The findings appear relevant to age-associated pathogenesisof cataracts and their possible attenuation. In addition, they provide a basis of pathogenesis in other ocular tissues such as the macula known to undergo age-dependent degeneration.     

A new chiral Rh(II) catalyst for enantioselective [2 + 1]-cycloaddition. mechanistic implications and applications

A novel chiral Rh(II) catalyst (1) is introduced for the [2 + 1]-cycloaddition of ethyl diazoacetate to terminal acetylenes and olefins with high enantioselectivity. The catalyst 1 consists of one acetate bridging group and three mono-N-triflyldiphenylimidazoline-2-one bidentate ligands (DPTI) spanning the Rh(II)-Rh(II) metallic center in a structure that was determined by single-crystal X-ray diffraction analysis. A rational mechanism is advanced that provides a straightforward explanation for the enantioselectivity and absolute stereochemical course of the [2 + 1]-cycloaddition reactions. A key element in this explanation is the cleavage of one of the Rh-O bonds of the bridging acetate group in the intermediate Rh-carbene complex to form a new pentacoordinate Rh carbene complex (formally 1.5 valent Rh) that can undergo [2 + 2]-cycloaddition with the C-C pi-bond of the acetylenic or olefinic substrate. Reductive elimination of the resulting adduct affords the cyclopropene or cyclopropane product. The C2-symmetry of the two DPTI ligands orthogonal to the bridging acetate also contributes to the high observed enantioselectivity and mechanistic clarity. The catalyst 1, which functions effectively at 0.5 mol %, can be recovered efficiently for reuse. Its ready availability, robustness, and effectiveness suggest it as a useful addition to the list of practical chiral Rh(II) catalysts for synthesis.     

Aziridination Reactivity of a Manganese(II) Complex with a Bulky Chelating Bis(Alkoxide) Ligand

Treatment of Mn(N(SiMe₃)₂)₂(THF)₂ with bulky chelating bis(alkoxide) ligand [1,1′:4′,1′′-terphenyl]-2,2′′-diylbis(diphenylmethanol) (H₂[O-terphenyl-O]^Ph) formed a seesaw manganese(II) complex Mn[O-terphenyl-O]^Ph(THF)₂, characterized by structural, spectroscopic, magnetic, and analytical methods. The reactivity of Mn[O-terphenyl-O]^Ph(THF)₂ with various nitrene precursors was investigated. No reaction was observed between Mn[O-terphenyl-O]^Ph(THF)₂ and aryl azides. In contrast, the treatment of Mn[O-terphenyl-O]^Ph(THF)₂ with iminoiodinane PhINTs (Ts = p-toluenesulfonyl) was consistent with the formation of a metal-nitrene complex. In the presence of styrene, the reaction led to the formation of aziridine. Combining varying ratios of styrene and PhINTs in different solvents with 10 mol% of Mn[O-terphenyl-O]^Ph(THF)₂ at room temperature produced 2-phenylaziridine in up to a 79% yield. Exploration of the reactivity of Mn[O-terphenyl-O]^Ph(THF)₂ with various olefins revealed (1) moderate aziridination yields for p-substituted styrenes, irrespective of the electronic nature of the substituent; (2) moderate yield for 1,1′-disubstituted α-methylstyrene; (3) no aziridination for aliphatic α-olefins; (4) complex product mixtures for the β-substituted styrenes. DFT calculations suggest that iminoiodinane is oxidatively added upon binding to Mn, and the resulting formal imido intermediate has a high-spin Mn(III) center antiferromagnetically coupled to an imidyl radical. This imidyl radical reacts with styrene to form a sextet intermediate that readily reductively eliminates the formation of a sextet Mn(II) aziridine complex.     

Metabolism of levamisole and kinetics of levamisole and aminorex in urine by means of LC-QTOF-HRMS and LC-QqQ-MS

The antihelminthic drug Levamisole can enhance cocaine effects by conversion into the amphetamine-like drug aminorex. We describe an LC-MS method for the determination of levamisole and its metabolite aminorex in human urine. Selectivity is given, calibration curves were linear within the calibration range 2.5–250 ng/mL; limits of the method were LoD 0.51 ng/mL, LoQ 1.02 ng/mL for levamisole and LoD 0.65 ng/mL, LoQ 0.76 ng/mL for aminorex. Precision data was in accordance with the guidelines (intraday precision for aminorex ranged between 5.75 and 11.0 % for levamisole between 8.36 and 10.9 %; interday precision for levamisole 10.9–16.9 % and for aminorex 7.64–12.7 %; accuracy data for levamisole ?1.96 to –14.3 % and for aminorex?11.9 to–18.5 %). The validated method was successfully applied to study the urinary excretion of levamisole after the administration of 100 mg of levamisole orally. Levamisole and aminorex could be detected in post-administration urine samples. Levamisole could be detected up to 39 h after ingestion, while aminorex was detectable up to 54 h. Maximum aminorex concentrations were 45 ng/mL urine. Further metabolites of levamisole after oral ingestion by means of liquid chromatography hybrid quadrupole time-of-flight high-resolution mass spectrometry (LC-QTOF-HRMS) were identified. Only 0.5 % of the ingested drug was quantified as unchanged levamisole in urine. Besides aminorex, five isomers of aminorex and 4 hydroxy-metabolites of aminorex or its isomers were found. Furthermore, levamisole is also hydroxylated and eliminated free or conjugated with sulfate or glucuronide into urine.